An enhanced RRM2 siRNA delivery to rheumatoid arthritis fibroblast-like synoviocytes through a liposome‑protamine-DNA-siRNA complex with cell permeable peptides

Wang,Xin; Wang,Xueping; Sun,Jin; Fu,Shiou

doi:10.3892/ijmm.2018.3815

An enhanced RRM2 siRNA delivery to rheumatoid arthritis fibroblast-like synoviocytes through a liposome‑protamine-DNA-siRNA complex with cell permeable peptides

Authors:
- Xin Wang
- Xueping Wang
- Jin Sun
- Shiou Fu
View Affiliations

Affiliations: The First Department of Pain Management, Qingdao Municipal Hospital, Qingdao, Shandong 266011, P.R.China, The Second Department of Pain Management, Qingdao Municipal Hospital, Qingdao, Shandong 266011, P.R. China, International Joint Cancer Institute, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: August 8, 2018 https://doi.org/10.3892/ijmm.2018.3815
Pages: 2393-2402
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Rheumatoid arthritis (RA) is considered to be a systemic autoimmune disease that induces systemic complications and progressive disability. It affects a large number of people. RA fibroblast‑like synoviocytes (RA‑FLS) promote the progression of RA through the secretion of proinflammatory cytokines and increasing invasiveness into the extracellular matrix. Therefore, targeting RA‑FLS represents a potential approach for the treatment of RA. Ribonucleotide reductase M2 (RRM2), a critical protein for DNA synthesis and repair, may promote the proliferation of cells and inhibit cellular apoptosis. In previous studies it has been confirmed that the suppression of RRM2 markedly suppressed the proliferation of liver cancer cells. In the present study, a cell permeable peptide‑conjugated liposome‑polycation‑DNA (LPD) complex loaded with RRM2 small interfering RNA (siRNA) (CCP‑LPDR) was developed, aiming to increase the levels of apoptosis and inhibit the proliferation of RA‑FLS. CCP‑LPDR is a small‑sized molecule (~130 nm) with high encapsulation efficiency of siRNA (>90%) and high stability. Furthermore, it was verified that CCP‑LPDR markedly suppressed RRM2 gene and protein expression by ~80%. Notably, CCP‑LPDR efficiently targeted RA‑FLS, resulting in a marked decrease in the proliferation and increase in the level of apoptosis in RA‑FLS. In addition, the levels of proinflammatory cytokines tumor necrosis factor‑α and interleukin‑6 were markedly decreased in RA‑FLS following CCP‑LPDR treatment. Therefore, CCP‑LPDR may efficiently deliver RRM2 to RA‑FLS and represent a potential treatment for RA.

View Figures

View References

1	Mclnnes IB and Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med. 365:2205–2219. 2011. View Article : Google Scholar
2	Glant TT, Mikecz K and Rauch TA: Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med. 12:352014. View Article : Google Scholar : PubMed/NCBI
3	Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, Casado G, Detert J, El-Zorkany B, Emery P, et al: Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: Results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 73:62–68. 2014. View Article : Google Scholar :
4	Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, O'Fallon WM and Matteson EL: Survival in rheumatoid arthritis: A population-based analysis of trends over 40 years. Arthritis Rheum. 48:54–58. 2003. View Article : Google Scholar : PubMed/NCBI
5	Kobelt G and Jönsson B: The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments. Eur J Health Econ. 8(Suppl 2): S95–S106. 2008. View Article : Google Scholar
6	Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ and Xu J: Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies. Bone Res. 6:152018. View Article : Google Scholar : PubMed/NCBI
7	Boechat Nde O, Ogusku MM, Boechat AL and Sadahiro A: Interaction between smoking and HLA-DRB1*04 gene is associated with a high cardiovascular risk in Brazilian Amazon patients with rheumatoid arthritis. PLoS One. 7:e415882012. View Article : Google Scholar
8	Bartok B and Firestein GS: Fibroblast-like synoviocytes: Key effector cells in rheumatoid arthritis. Immunol Rev. 233:233–255. 2010. View Article : Google Scholar : PubMed/NCBI
9	Konisti S, Kiriakidis S and Paleolog EM: Hypoxia - a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nat Rev Rheumatol. 8:153–162. 2012. View Article : Google Scholar : PubMed/NCBI
10	Tang Q, Cui J, Tian Z, Sun J, Wang Z, Chang S and Zhu S: Oxygen and indocyanine green loaded phase-transition nanoparticle-mediated photo-sonodynamic cytotoxic effects on rheumatoid arthritis fibroblast-like synoviocytes. Int J Nanomedicine. 12:381–393. 2017. View Article : Google Scholar : PubMed/NCBI
11	Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 23:1539–1548. 2004. View Article : Google Scholar
12	Zhang K, Hu S, Wu J, Chen L, Lu J, Wang X, Liu X, Zhou B and Yen Y: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: Implication of RRM2 in angiogenesis. Mol Cancer. 8:112009. View Article : Google Scholar : PubMed/NCBI
13	Shao J, Zhou B, Chu B and Yen Y: Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets. 6:409–431. 2006. View Article : Google Scholar : PubMed/NCBI
14	Gao J, Chen H, Yu Y, Song J, Song H, Su X, Li W, Tong X, Qian W, Wang H, et al: Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA. Biomaterials. 34:10084–10098. 2013. View Article : Google Scholar : PubMed/NCBI
15	Roman-Blas JA and Jimenez SA: NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage. 14:839–848. 2006. View Article : Google Scholar : PubMed/NCBI
16	Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y, et al: Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum. 42:2532–2542. 1999. View Article : Google Scholar
17	Gao J, Liu W, Xia Y, Li W, Sun J, Chen H, Li B, Zhang D, Qian W, Meng Y, et al: The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials. 32:3459–3470. 2011. View Article : Google Scholar : PubMed/NCBI
18	Gao J, Yu Y, Zhang Y, Song J, Chen H, Li W, Qian W, Deng L, Kou G, Chen J, et al: EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma. Biomaterials. 33:270–282. 2012. View Article : Google Scholar
19	Gao J, Sun J, Li H, Liu W, Zhang Y, Li B, Qian W, Wang H, Chen J and Guo Y: Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials. 31:2655–2664. 2010. View Article : Google Scholar
20	Xu C, Lee SA and Chen X: RNA interference as therapeutics for hepatocellular carcinoma. Recent Pat Anticancer Drug Discov. 6:106–115. 2011. View Article : Google Scholar
21	Gao H, Zhang Q, Yu Z and He Q: Cell-penetrating peptide-based intelligent liposomal systems for enhanced drug delivery. Curr Pharm Biotechnol. 15:210–219. 2014. View Article : Google Scholar : PubMed/NCBI
22	Koren E and Torchilin VP: Cell-penetrating peptides: Breaking through to the other side. Trends Mol Med. 18:385–393. 2012. View Article : Google Scholar : PubMed/NCBI
23	Jha D, Mishra R, Gottschalk S, Wiesmüller KH, Ugurbil K, Maier ME and Engelmann J: CyLoP-1: A novel cysteine-rich cell-penetrating peptide for cytosolic delivery of cargoes. Bioconjug Chem. 22:319–328. 2011. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔ^C T method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Srirangan S and Choy EH: The role of interleukin-6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2:247–256. 2010. View Article : Google Scholar : PubMed/NCBI
26	Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M and Quintana A: Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 9:522008. View Article : Google Scholar : PubMed/NCBI
27	Lee H, Lytton-Jean AK, Chen Y, Love KT, Park AI, Karagiannis ED, Sehgal A, Querbes W, Zurenko CS, Jayaraman M, et al: Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol. 7:389–393. 2012. View Article : Google Scholar : PubMed/NCBI
28	Tseng YC, Mozumdar S and Huang L: Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev. 61:721–731. 2009. View Article : Google Scholar : PubMed/NCBI